Clinical Trials Browser

Interventional × Nonseminomatous germ cell tumor × Clear all

NCT02115165 2026-04-06

CABA-GCT

Phase 2 Completed

Nonseminomatous germ cell tumor

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Phase 2 Active not recruiting

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT04876456 2026-01-15

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Phase 2 Active not recruiting

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Seminoma

NCT05634785 2026-01-09

CD30 CAR for CD30+ NSGCT

Phase 2 Completed

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal

NCT06133543 2025-09-15

RAISN

Phase NA Recruiting

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Seminoma

NCT06418789 2025-08-03

GERMAN

Phase 2 Recruiting

Nonseminomatous germ cell tumor, Choriocarcinoma, Neoplasms, Germ Cell and Embryonal, Teratoma, Germinoma, Seminoma, Endodermal Sinus Tumor

NCT06967961 2025-07-29

DP-PAN-CANCER

Phase NA Recruiting

DermatologicGenitourinaryGynecologicSarcoma

Nonseminomatous germ cell tumor, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT05705687 2025-05-08

VAPOR

Phase NA Recruiting

Nonseminomatous germ cell tumor

NCT04804007 2025-04-18

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Phase 2 Recruiting

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal

NCT02375204 2025-01-13

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Phase 3 Active not recruiting

Nonseminomatous germ cell tumor, Choriocarcinoma, Neoplasms, Germ Cell and Embryonal, Teratoma, Germinoma, Seminoma, Endodermal Sinus Tumor

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02499952 2022-07-11

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Phase 2 Terminated

12 enrolled 14 charts

GenitourinaryGynecologic

Nonseminomatous germ cell tumor, Genital Neoplasms, Female, Genital Neoplasms, Male, Mediastinal Neoplasms, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms

NCT02317393 2020-07-09

TERMATEP

Phase 2 Completed

Nonseminomatous germ cell tumor, Neoplasm Metastasis

NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Phase 2 Terminated

18 enrolled 13 charts

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal